StemCell Therapy

UNITY Biotechnology, a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, announced the closing of an additional$35 millionin Series B financing. This second close of the Series B, in addition to the initial close infall of 2016, brings the total amount of this financing to$151 million.

The UNITY Series B financing ranks among the largest private financings in biotech history. New Series B investors include INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha Limited.These new investors join the Series B led by longtime life science investors ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock. Other investors include Bezos Expeditions, Vulcan Capital, Founders Fund, WuXi PharmaTech, and Mayo Clinic Ventures. Proceeds from this financing will be used to expand ongoing research programs in cellular senescence and advance the first preclinical programs into human trials.

UNITYalsoannounced thatGraham Cooperhas joined UNITY's board of directors. Mr. Cooper was previously the chief financial officer ofReceptos,which was acquired by Celgene in 2015 for$7.8 billion.

"We are incredibly fortunate to have attracted someone of Graham's experience and judgment to help us shape our mission of attacking diseases of aging and fundamentally reshaping human healthspan," saidKeith Leonard, UNITY chairman and CEO. "The incredible investor support matched with the progress in preclinical development has us on track to initiate clinical trials in 2018 with our first senolytic drug."

"UNITY pairs a huge market opportunity with highly compelling biology and a proven and experienced management team. We continue to attract both a highly skilled team and deep financial backing to match the potential," saidRobert Nelsen, UNITY board member and co-founder and managing director of ARCH Venture Partners, UNITY's founding investor.

Go here to read the rest:
UNITY Biotechnology Announces Series B Financing Extension ... - Drug Discovery & Development

Shares ofProShares Ultra Nasdaq Biotechnology (BIB) have seen the needle move3.41% or 1.75 in the most recent session. TheNASDAQ listed companysaw a recent bid of $53.03 on83915 volume.

Strictly technical traders typically dont pay a whole lot of attention to fundamental factors such as value, competition, or company management. Technical analysts want to figure out trends based on indicators, charts, and prior price data. These types of traders are usually highly active and hold positions for short periods of time in order to capitalize on short-term price fluctuations. Active traders may be quick to unload a position if it does not pan out as expected. Technicians often pay a great deal of attention to support and resistance levels. These are levels where traders believe a specific stock will either see a bounce or a pullback.

Digging deeping into the ProShares Ultra Nasdaq Biotechnology (BIB) s technical indicators, we note that the Williams Percent Range or 14 day Williams %R currently sits at -54.70. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

ProShares Ultra Nasdaq Biotechnology (BIB) currently has a 14-day Commodity Channel Index (CCI) of -31.41. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Currently, the 14-day ADX for ProShares Ultra Nasdaq Biotechnology (BIB) is sitting at 20.96. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, the 14-day RSI for ProShares Ultra Nasdaq Biotechnologyis currently at 47.24, the 7-day stands at 50.69, and the 3-day is sitting at 71.69.

See the original post here:
Shares Seesawing on Volume: ProShares Ultra Nasdaq Biotechnology (BIB) - Morgan Research

Park Ophthalmology is a full service eye care center dedicated to serving the needs of your entire family. We have locations in the Research Triangle Park area and North Raleigh for your convenience. We are currently accepting new patients.

Our board certified physicians provide a wide variety of medical and surgical treatments of eye diseases, including glaucoma, cataracts, corneal disease, dry eye syndrome, and diabetic eye disease. We perform general vision exams, specialty dry eye evaluations, contact lens evaluation and fitting, eye safety information, and sports medicine protective eyewear and counseling. Surgical procedures include small incision cataract surgery, glaucoma surgery, laser surgery, and emergency eye treatments.

Our philosophy of health care is geared toward the prevention and treatment of eye diseases, with education, counseling, and personalized service. Early detection is the best defense against permanent vision loss. We are dedicated to providing sophisticated, advanced eye care in a warm and caring environment.

Many questions and interactions with our practice are best handled via the secure Patient Portal Click on the logo below to login to the Patient Portal.

Read the original post:
Park Ophthalmology | Durham & Raleigh NC | Beth Friedland, MD

Andrew McClellan (Courtesy of: Texas Retina Associates)

Dallas-based Texas Retina Associates has added Dr. Andrew McClellan to its Dallas-Fort Worth practice. He starts on September 1.

TRA has 14 offices throughout Texas and is the states largest opthalmology practice, employing 210 physicians and medical staffers. The company focuses on the diagnosis and medical and surgical management of retina and vitreous diseases.

McClellan is an ophthalmologist specializing in the treatment of macular degeneration, retinal tears and detachment, diabetic retinopathy, and macular holes. He will work with patients in the Fort Worth, Wichita Falls, and Grapevine TRA offices.

He most previously served as an ophthalmologist at Bascom Palmer Eye Institute in Miami, Fla..

TRA Jeff Brockette said in a statement: McClellan comes to us with stellar training and experience from one of the top-rated eye hospitals in the country, and we are honored to have him join our practice. He shares our commitment to providing patients with convenient access to the latest sight-saving treatment options and doing so in a compassionate, personalized manner.

McClellan earned his bachelors degree from Vanderbilt University in Nashville, Tenn. He earned his M.D. from Baylor College of Medicine in Houston, and completed his internship at Mount Sinai Medical Center in Miami, Fla.

More here:
Texas Retina Associates Adds Specialist - D Healthcare Daily

A Portland man who watched a solar eclipse in 1963 says the experience left him partially blind in one eye, and now he wants everyone to know the warnings about eye damage during the upcoming eclipse are no joke.

PORTLAND, Oregon A Portland man who watched a solar eclipse in 1963 says the experience left him partially blind in one eye, and now he wants everyone to know the warnings about eye damage during the upcoming eclipse are no joke.

Back then, it was a total solar eclipse in Alaska and Canada, but the path of totality did not come through Oregon.

Still, Louis Tomososki remembers being 16 years old and watching it unfold from the baseball field at Marshall High School.

Nobody was talking about safety glasses back then, so he watched it with the naked eye, closing his left eye and leaving his right eye open.

Oh 20 seconds probably, thats all it took, Tomososki told FOX 12. Im glad I didnt go 40 seconds, it would have been even worse.

He doesnt remember exactly when he realized there was a problem, but those few seconds burned a hole in his retina leaving him with a sizable blind spot hes had ever since.

He describes it as looking at someone and being able see their face but not their nose.

Tomososki remembers it was discovered during an eye exam when he went into the Air Force right after high school.

In the 54 years since that eclipse, he said the blind spot hasnt gotten any worse or any better.

Every time we go to an eye doctor now for an exam, they dilate your eyes and look in there, the first thing they say is, you looked at a solar eclipse sometime in your life, he said.

Dr. Brandon Lujan, an assistant professor of Opthalmology at OHSUs Casey Eye Institute, said the same damage can be done on any other day if you stare at the sun. But with the eclipse, even when the visible light is reduced by the moon, UV and infrared rays can still do damage to the retina.

Some damage occurs pretty quickly, but a lot of damage can take hours to days to really come to bear, Lujan said. Unfortunately theres not a treatment for it, so once that damage is done you have to wait and hopefully things improve and your body can heal some, but a lot of the damage can be permanent.

Its a lesson Tomososki wishes he knew back in 1963.

With Mondays total solar eclipse on the horizon, he wants you to remember that even a quick look at the sun with the naked eye just isnt worth it.

A quick look like we did back in 1963, and Im 71, almost 71 now, that quick look cost us, Tomososki said. And it could have cost us a lot more.

Source:KPTV

Originally posted here:
Man who was left partially blind by 1963 eclipse offers warning: 20 seconds is 'all it took' - myfox8.com

Sun worship is not new, in fact, the 14th century B.C. Egyptians worshiped the sun god in a religion known as Atonism. In modern times we acknowledge the crucial importance of the sun as our provider of life sustaining energy, but we generally do not worship it. This Monday, however, with the first total solar eclipse to cross the entire country coast-to-coast since 1918, the obsessive fascination with viewing it is bordering on religious fervor.

Is it safe to directly view the eclipse? Certainly not without special protective eyewear that comply with international safety standards for direct observation of the sun (ISO 12312-2). NASA has emphasized that the filter must be from an approved manufacturer. The American Astronomical Society has also provided tips for safe viewing as well a list of reputable manufacturers of eyewear. If you can see any objects including your hand in front of your face then the eyewear is definitely faulty. Across our land, eclipse glasses are selling out of pharmacies and photo stores much faster than they can be restocked, and libraries are holding onto them for special eclipse viewing sessions. Scalpers are asking prices usually reserved for sports playoff games.

Unfortunately, there is no proven treatment and though there is often improvement over time, some of the eye damage may be permanent, so the best idea is to avoid the exposure in the first place.

According to NASA, if you happen to be in the direct path of the total eclipse across the south/central U.S. you could theoretically choose the exact moment when the moon is directly positioned across the Sun and only the corona is visible to view the eclipse without eye protection. But to try to gauge that exact moment correctly could be risky too.

Dr. Joel Schuman, Chairman of Opthalmology at NYU Langone Health, told me that eyewear that meets the ISO 12312-2 standard should be safe, provided of course that it is in good condition and you wear it the entire time you are viewing the eclipse and not add on a magnifying telescope, binoculars, or camera. Dr. Martin Leib, professor of pphthalmology at Columbia University, said that he thinks that the safest way to view the eclipse is with your back to the sun, cutting a tiny hole in a paper plate and allowing the image of the eclipse to pass through and project onto another paper plate for your safe viewing.

If you try to look directly at the sun on a normal day, your eyes will water and begin to burn if you stare for more than a minute or two. This discomfort will get you to turn away. With the eclipse, you can end up staring for longer and not even realizing you are damaging and scarring your retina (solar retinopathy) until later, when you begin to experience symptoms. A central part of the retina can be damaged (macula) and your vision may become less sharp, you may develop blind spots, see wavy instead of straight lines, and a central yellow spot may appear which develops into a red spot over several days or weeks. Unfortunately, there is no proven treatment and though there is often improvement over time, some of the damage may be permanent, so the best idea is to avoid the exposure in the first place.

Fascination with solar eclipses has damaged retinas (the essential camera of the eye) through history. There is a story that Isaac Newton himself viewed an eclipse through a mirror and ended up with temporary blindness.

Perhaps Newton was prescient in his fascination with eclipses, since the total solar eclipse of 1919 was used by British scientist Arthur Eddington to show that Newtons absolutes of space and time were incorrect and that Einsteins newer theory of relativity (that gravity affected light, space, and time) was more accurate.

Mondays total solar eclipse is not likely to have the same long term impact on scientific theory, though it is definitely exciting for all and a moment for our country to safely unite behind a celebration of natures wonder.

Marc Siegel, M.D. is a professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center. He has been a medical analyst and reporter for Fox News since 2008.

More:
Dr. Marc Siegel: Solar eclipse - science, safety, and wonder - Fox News

Yet despite it being the countrys leading source of pain and disability it remains a largely invisible and overlooked condition that is often dismissed as an old persons disease, even though the truth is that it can attack people of all ages.

This is why Arthritis Research UK is launching a campaign to highlight the condition and its awful debilitating effects. Apart from the physical toll, it costs the economy 2.58billion a year.

There are always medical conditions that attract the publics attention and their sympathy. Arthritis is not one of these: it is almost a Cinderella illness. And most who suffer from it tend to do so in silence. Often they do not wish to be a nuisance to their families, let alone the medical profession.

Yet nobody would wish chronic pain on anybody. It can make life unbearable and many with arthritis are in pain all the time.

Many people with agonising conditions of all types will be stoical and put up and shut up. But with a disease such as arthritis and related illnesses such as osteoarthritis and rheumatoid arthritis, the very fact that it is so widespread makes it essential that the campaign not only raises awareness but also leads to more research and eventually a cure.

Brexit makes us safer

Our new chief trade negotiator Crawford Falconer will this week begin working alongside Liam Fox in the Department for International trade. In the run-up toBrexithis role will be crucial and it is to be welcomed that here is a senior figure who is wholeheartedly committed to getting the best out of quitting the EU.

Mr Falconer also believes that new alliances and trade deals made by Britain will make the world a safer place. He says: Many countries still recognise that open-trade policies directed at engaging with others are at the core of any strategy to improve the global prospects for political openness and stability.

For too long we have heard nothing but doom-laden despair at the complexity of extricating ourselves from Brussels with some even saying it is a job that simply cant be done. How refreshing to hear such a positive and optimistic attitude to Brexit.

Bake Off - we missed you

The new Bake Off, it must be admitted, looks very much like the old Bake Off though with some different people. The appeal of the show was always its gentle and quintessentially British charm, which thankfully seems intact.

Read more:
Arthritis: Invisible illness causing untold pain to sufferers - EXPRESS COMMENT - Express.co.uk

Arthritis sufferers forced to take time off work will cost the economy 3.43 billion a year by 2030, according to new research.

The two most common forms of the condition, osteoarthritis and rheumatoid arthritis, currently cost the UK economy 2.58 billion annually through 25 million lost working days.

But this will jump further by 900,000 more lost working days for the condition which costs the NHS and the wider healthcare system 10.2 billion every year.

Over the course of the next decade, an estimated 118.6 billion will be spent on the condition.

The figures were published by Arthritis Research UK, which is launching a campaign to raise the profile of the condition.

The research detailed in the report titled the Nations Joint Problem report, reveals the current and future impact of the condition on the economy, the NHS as well as families and individuals across the UK.

One-in-six people currently have OA and RA, and this is predicted to rise to one-in-five by 2050.

Experts predict that by then the figures will increase to 27.2 million working days and, an annual cost of 4.74 billion.

Arthritis is an umbrella term used to describe painful conditions that affect the bones, muscles and joints in all parts of the body.

Even though nine-in-ten people with arthritis (88%) describe it as a debilitating and life-restricting condition, the report reveals the condition is largely invisible from the public and even an acceptable, part of getting older.

The research suggests sufferers find there is also a stigma attached to the condition, which is often dismissed as an old persons disease, even though arthritis impacted on people of all ages.

Anne Kearl, 55, who has osteoarthritis, said: Pain is normal to me. Its always there. I may paint a smile on my face, but I will be hurting all over.

"Its had a big impact on my mental health; pain and depression feed off each other and in my experience, its hard to separate them out a lot of the time.

"I never know when I wake up if Im going to have a good day or a just got to get through it day. Thats the reality for me of living with arthritis.

"Because arthritis is invisible people other than my family dont see the reality. When friends and colleagues cant physically see anything wrong with you, they assume youre OK and often I let people think that rather than be honest about my arthritis."

Liam OToole, Chief Executive of Arthritis Research UK, said: "There is a complete mismatch between the enormous impact arthritis has on individuals, their families and society and the attention, priority and resources society currently gives to it.

"As a result, people with arthritis do not get the help or support that they need. We are all losing out.

"Whether its an employer who loses out on the skills of an employee, a child who misses out on playing with their parents or grandparents, the strain on the NHSs resources, or someone with arthritis who is trying to get through every day in pain, the impact of arthritis is being felt across the whole of society."

More here:
'Invisible' arthritis to cost UK economy 3.43 billion a year through sufferers taking time off work - Mirror.co.uk

Infographic courtesy of Gout and Uric Acid Education Society.

The community is invited to attend and support the 2017 Walk to Cure Arthritis on Saturday, Aug. 26, to help raise awareness and funding in the effort to find a cure for arthritis. The fundraising event will be held at Liliuokalani Park at 189 Lihiwai Street in Hilo and registration can be completed online.

Arthritis is a growing condition in Hawaii with roughly 19 percent of residents affected by some form of the condition, according to the Centers for Disease Control. Health experts say its important to speak with a rheumatologist to discuss treatment options in suspected cases.

In light of the upcoming Walk for Arthritis fundraiser, 70-year-old Hawaii Island resident Dennis Leatherman is sharing his story of suffering with chronic gout, an inflammatory arthritic condition that can lead to severe pain and joint damage.

Gout is caused by too much uric acid in the bloodstream, and can lead to sudden episodes of pain, stiffness and swelling. For many people the pain is overwhelming. It usually begins in the big toe and when left untreated, can spread to the ankles, heels, knees, wrists and fingers.

As a local art teacher and artist, Leatherman said the severity of his pain made him doubt whether he could continue painting. After multiple doctor visits and years of pain, Leatherman was finally diagnosed with chronic gout. He now leads an art class as a therapeutic activity for local residents struggling with various health conditions.

Only 10 percent of people with gout receive proper treatment, according to the Gout and Uric Acid Education Society.Leatherman hopes that sharing his own story will raise awareness about gout so others can get proper treatment if they notice symptoms.

Visit link:
2017 Walk to Cure Arthritis Comes to Hilo Aug. 26 - Big Island Now

The condition is three more times as common in men than women and symptoms tend to develop gradually, sometimes over many years.

Now experts have revealed the pain and the extreme tiredness which the condition causes can have a major impact on quality of life for people with the condition.

Scientists said this suggests new approaches to treating this painful condition may be needed.

Ankylosing spondylitis causes back pain, stiffness, fatigue and impaired mobility that develops over time.

There is no cure for AS at the moment.

However, a new study has shed light on some of the most prevalent modifiable factors that predict a poor quality of life in people with ankylosing spondylitis.

The University of Aberdeen research has indicated that some of these factors - which include pain, fatigue and poor physical function - are currently better monitored than others.

The study analysed data from 959 patients involved in the Scotland Registry for Ankylosing Spondylitis, which collected clinical and patient-reported data on ankylosing spondylitis from across Scotland.

A total of five factors were identified as independent predictors of a poor quality of life among patients: moderate to severe fatigue, poor physical function, chronic widespread pain, high disease activity and poor spinal mobility.

Physical function is generally monitored using a tool called the Bath Ankylosing Spondylitis Functional Index (BASFI), while the Bath

Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity, and the Bath Ankylosing Spondylitis Metrology Index (BASMI) is used to assess spinal mobility.

However, this leaves two factors - chronic widespread pain and fatigue - that do not receive the same attention.

It was suggested that the nonspecific nature of these symptoms may explain why they are not traditionally monitored in ankylosing spondylitis to the same degree.

However, given the important role they play in patients' quality of life, it could be beneficial for these trends to be monitored more closely.

The researchers said: "These findings provide evidence that in addition to traditional clinical targets (BASDAI, BASFI and BASMI), focus on nonspecific symptoms (chronic widespread pain and fatigue) - perhaps with non pharmacological therapies - may yield important improvements in quality of life."

Dr Devi Rani Sagar, research liaison manager at Arthritis Research UK, said: "Ankylosing spondyloarthritis is an incredibly painful condition, which affects 200,000 people in the UK and can dramatically reduce a person's quality of life, making everyday activities such as walking to the shops and standing in the kitchen extremely difficult.

"This new study demonstrates the impact that pain and fatigue can have on quality of life for people with this condition, and that monitoring these symptoms may help to give a better indication of the success of treatments.

We welcome more research to find effective ways to reduce pain and fatigue to help make everyday life better for people with arthritis."

Woman's arthritis symptoms were cured with miracle device previously used on horses.

See the rest here:
Back pain and fatigue? Symptoms could be warning sign of THIS form of arthritis - Express.co.uk

By Jane Brody

When a physically active person like me injures a joint, especially one as crucial as a knee or ankle, one of the first thoughts is likely to be How fast can I get back to my usual activities?

That kind of thinking, however, could set the stage for a painful chronic problem years later: post-traumatic osteoarthritis.

In the rush to get back in the game whether as part of a team or elite sport or simply a cherished recreational activity like jogging or tennis it is tempting to short-circuit the rehabilitation needed to allow the joint to heal fully. But adequate recovery, including rehab measures aimed at strengthening structures that support the injured joint, is critical to maximize its stability, reduce the risk of re-injury and head off irreparable joint damage.

And you dont have to be a senior citizen to pay the price of failing to build up the tissues that help protect that joint. Studies have shown that when an adolescent or young adult suffers a knee injury, for example, X-ray evidence of arthritis is often apparent within a decade.

As a team of orthopedists and rehabilitation specialists from the University of Iowa explained, Recent research suggests that acute joint damage that occurs at the time of an injury initiates a sequence of events that can lead to progressive articular surface damage. That means deterioration of the surface of the bone itself and the connecting tissues that cushion and stabilize bones of a joint like the knee, which is what arthritis is all about.

Osteoarthritis afflicts some 27 million Americans, and that number will certainly grow with the increase in obesity, the current emphasis on lifelong physical activity and the aging of the population. It is a degenerative joint disease that occurs when the protective cartilage on the ends of bones and often the surface of the bones themselves wear down, causing pain, stiffness, instability and disability that can interfere with work and mobility and diminish quality of life.

The Iowa team noted that arthritis will eventually develop in more than 40 percent of people who seriously injure the ligaments (the stabilizing bands that connect bones to one another); the meniscus (the crescent-shaped cartilage that cushions the knee and certain other joints), or the articular surface of a joint. People with a history of trauma to the knee, for example, are three to six times more likely to develop arthritis in that knee. Even without an acute injury, highly repetitive impact on a joint can damage the articular cartilage.

This may help to explain why I ended up with bone-on-bone arthritis and had to replace both knees at age 63. I had suffered three ligament injuries (while skiing) and after years of running and singles tennis, the meniscus in both knees had shredded. Although I did the recommended physical therapy after each injury, I now know that I was not sufficiently diligent about maintaining the strength and flexibility of the supporting muscles and other tissues that might have better protected my knees for years longer.

A consensus statement in the Journal of Athletic Training said that arthritis should no longer be considered a disease that affects only the elderly.

Increasing evidence demonstrates that young and middle-age adults are suffering from osteoarthritis as well, the statement said. More than half of adults with symptomatic knee osteoarthritis are younger than 65.

In fact, as Joseph M. Hart, an athletic trainer who conducts clinical research at the University of Virginia, and his colleagues wrote in the journal, A 17-year-old athlete who tears her anterior cruciate ligament could develop osteoarthritis before she turns 30, potentially leading to chronic pain and disability. Damage to this ligament, in the center of the knee, is the most common injury among young athletes, especially girls, they wrote.

Jeffrey B. Driban, an athletic trainer at Tufts Medical Center in Boston, said that one person in three who injures the anterior cruciate ligament will have X-ray evidence of osteoarthritis within 10 years whether or not the injury is repaired surgically.

Driban and co-authors pointed out that some sports soccer, elite-level long-distance running, competitive weight lifting and wrestling are associated with a higher risk of knee injuries.

Sports participants who suffer a knee injury can minimize the risk of reinjury and arthritis, Driban said, by not rushing back into activity or trying to play through pain. They must strengthen the muscles that support the joint the quads, hamstrings and hip muscles. Its important to think about the entire lower extremity, not just the knee.

After an injury, an athletic trainer, rehabilitation specialist or physical therapist who specializes in orthopedics can evaluate a persons muscle strength, endurance, balance and movement quality, then guide recovery with a structured rehab program that is maintained for six to nine months, Hart said.

It is also important to continue to pursue an active lifestyle, said Abby C. Thomas of the University of North Carolina at Charlotte.

You may have to modify the activities you do, but you have to stay active to maintain strength and cardiovascular fitness without putting repetitive stress on a joint thats already injured, she said. If your knee hurts and you cant run, maybe get on a bike or swim, activities that place less stress on the knees.

Dont sit around on the couch because running hurts, Thomas said. Try walking, or something different, but dont give up on physical activity.

Lifelong activity is also important to prevent weight gain, since every extra pound places disproportionate stress on the knees. All the authors emphasized that pursuing a healthy lifestyle is crucial for everyone, not just elite athletes and those who play on school teams.

Go here to see the original:
Brody: Time after a joint injury can fend off arthritis - Sarasota Herald-Tribune

Dear Doctor: We were shocked when our daughter, who is 26, was diagnosed with rheumatoid arthritis. I thought arthritis was something that elderly people got. What treatments are available and what are our daughter's prospects for an active and healthy life?

Dear Reader: We're very sorry to hear about the medical challenge your family is facing and hope the information we offer will be of help.

When it comes to what is commonly referred to as "arthritis," we're actually talking about two different conditions. Osteoarthritis, which is the type of arthritis you're thinking of in regards to a more elderly population, is a degenerative disease. In osteoarthritis, the tissues of the joints deteriorate due to wear and tear. When the cartilage that cushions the joints begins to break down, it leads to swelling, stiffness and pain.

Rheumatoid arthritis, or RA, is an inflammatory autoimmune disease. Joint damage occurs because the immune system has gone haywire and begins to target the body's own tissues. Although RA most commonly affects the joints, it can also involve other parts of the body, including the lungs, digestive system, circulatory system, skin and eyes.

In the United States, about 1.5 million people (more women than men) are living with RA. It generally doesn't appear until the 40s, and becomes increasingly common as we hit our 50s and beyond, but cases in younger people are not rare.

The most common sites of inflammation in RA are the wrists and the finger joints closest to the palm. However, the knees, neck, ankles, feet, elbows and shoulders can also be involved. RA has a symmetrical pattern, so the joint on each side of the body is usually affected. In addition to that symmetry, symptoms of RA include tender and swollen joints, a feeling of warmth within the joints, fatigue and occasional fever. For many people, prolonged morning stiffness or difficulty moving again following a long period of inactivity can be some of the early signs of RA.

Treatment is tailored to each person's symptoms. Your daughter's rheumatologist will discuss lifestyle changes to address inflammation. This includes using special tools or aids to help with difficult tasks, pursuing the right kind of exercise -- hatha yoga has been found to be helpful -- and striking the optimal balance between activity and rest.

Eating a well-balanced anti-inflammatory diet can help manage RA symptoms. This treatment approach got a boost recently when a study found that RA patients who ate fish twice a week (baked, steamed, raw or broiled, but not fried) scored measurably lower on a standardized scale that measures disease activity.

Some medications for RA address pain and inflammation. Others take aim at the disease process itself. All have potential side effects, so urge your daughter to learn the risks and benefits of any proposed medication.

Looking to the future, advances in immunotherapy and the expanding study of the ever-surprising gut biome offer hope for RA sufferers. In the meantime, prompt treatment is crucial. Make sure your daughter finds a good rheumatologist she likes and begins her medical care.

Eve Glazier, M.D., MBA, is an internist and assistant professor of medicine at UCLA Health. Elizabeth Ko, M.D., is an internist and primary care physician at UCLA Health.

Send your questions to askthedoctors@mednet.ucla.edu, or write: Ask the Doctors, c/o Media Relations, UCLA Health, 924 Westwood Blvd., Suite 350, Los Angeles, CA, 90095. Owing to the volume of mail, personal replies cannot be provided.

View original post here:
Treatments for rheumatoid arthritis unique to individual patient ... - Beatrice Daily Sun

Updated 7 hours ago

Carl W. Miller of Irwin started collecting guns in high school, became a marksman in the Army National Guard and spent more than 45 years teaching hunter/trapper courses in area sportsmen clubs.

He loved it, said his daughter Colleen Stubbs. He enjoyed (teaching) and they counted on him.

Mr. Miller became interested in firearms from when he could carry one in his hands, said his sister, Mary Ann Brown.

He reloaded his own ammunition. Shortly before his death, he was asking if she was interested in selling a Mossberg rifle owned by her late husband, she said.

It was his passion, she said.

Carl W. Miller died Friday, Aug. 18, 2017, in Excela Westmoreland Hospital. He was 82.

He was born July 11, 1935, in Arona, the son of the late Lawrence J. and Violet Miller.

He joined the Army National Guard in 1954 and attained the rank of sergeant in the 110th Infantry, his family said.

He was on active duty during part of his six-year enlistment.

Mr. Miller retired from CTP Carrera Inc. in Latrobe, where he was a quality assurance technician.

He was a member of American Legion Post No. 359 in Irwin and the National Rifle Association.

Her brother was a prankster who liked to wait until the tensest moment in a horror movie to yell boo, Brown said. He was a bundle of laughter and fun.

Diagnosed with rheumatoid arthritis in the 1960s, he didn't allow the inflammatory joint disease to stop him from participating in shooting competitions as well as hunting and fishing, his daughter said. He also made muzzleloaders.

He was still able to target shoot and be very, very good, so he was very proud of that, Stubbs said.

Mr. Miller occasionally hunted elk in Colorado, but mainly hunted deer, turkey and small game in Pennsylvania and fished for trout in area streams, said his son Eric Miller of Greensburg. He had 50 to 60 guns in his collection.

He also enjoyed camping and taking vacations in Hilton Head and the Outer Banks.

He was easygoing, his son said. He got along with everybody.

Their father was a social butterfly who developed an interest in photography and video in the 1960s, Stubbs said.

At family reunions, Christmas parties and other gatherings, he was the man with the video camera long before most people had them, she said.

He had his own darkroom and collected cameras, his family said.

Whenever he traveled, his camera was always with him, Stubbs said.

His memberships included the Irwin Sportsmen's Club, the White Oak Road and Gun Club and the McKeesport Sportsmen's Association.

He was a member of as many as he could join, she said.

Mr. Miller was preceded in death by his wife of 36 years, Martha G. (Lash) Miller. He is survived by their four children, Denise Sager of Mt. Pleasant; Christine Trout and her husband, W. Ronald, of Richland; Colleen Stubbs and her husband, Jeff, of Erie; and Eric Miller and his wife, Terri, of Greensburg; 12 grandchildren, and two great-granddaughters.

A funeral service will be held at 11 a.m. Tuesday at the Joseph W. Nickels Funeral Home, 404 Sewickley Ave., Herminie. Interment with full military honors will follow at Westmoreland County Memorial Park, 150 East Side Drive, Hempfield.

Memorial donations may be made to the Arthritis Foundation, 790 Holiday Drive, Green Tree, PA, 15220.

Brian Bowling is a Tribune-Review staff writer. Reach him at 724-850-1218, bbowling@tribweb.com or via Twitter @TribBrian.

Read more:
Rheumatoid arthritis didn't stop Irwin man from enjoying the outdoors - Tribune-Review

TEL AVIV, Israel, Aug. 21, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second quarter ended June 30, 2017.

"We are very pleased with our accomplishments in the first half of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. "As planned, 2017 is turning into a transformative year for Cellect Biotechnology. Cellect initiated its Phase I/II study on cancer patients undergoing matched related allogeneic HSCT transplantation and reported positive results in the first patient followed by the approval to recruit two more patients. Further, Cellect held a pre-IND meeting with the FDA that was very positive and Cellect is moving ahead with its plan to submit an IND".

Important progress was achieved with the company's IP portfolio the major patent covering the composition of matter and use of the ApotainerTm was issued in US and Russia, the collaboration with Entegris was further consolidated by receiving a BIRDF non-equity grant, and the development of the Apotainer was accelerated.

In addition, world renowned leaders joined the Company (i.e KOLs from Harvard Medical school, executives from Pfizer and Merck) and the Company teamed up with Boston based Locust-Walk business development group for planning and launching a business development campaign before the end of the year.

During the second quarter, the Company made the following announcements -

Recent Corporate Highlights:

Second Quarter 2017 Financial Results:

Balance Sheet Highlights:

* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2017 (U.S. $1 = NIS 3.496).

The Company's consolidated financial results for the three and six months ended June 30, 2017 are presented in accordance with International Financial Reporting Standards.

About Cellect Biotechnology Ltd.

The Company is developing an innovative technology which enables the functional selection of stem cells based on their sensitivity to apoptosis. This functional-based selection is a breakthrough technology in the ability to isolate stem cells from any given tissue, and may improve a variety of stem cells applications.

The Company's first planned product line is expected to include unique containers for cell selection in an apoptosis-inducing microenvironment. Cellect's first planned commercial product candidate is a medical kit designed for the cancer treatment bone marrow transplantations market, as well as other markets which require cell selection. The Company plans that in the future its technology will be integrated in many production procedures of stem cell-based products.

The Company's securities are currently traded on both the NASDAQ Capital Market and the Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP").

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our anticipated performance in 2017, the expected characteristics of our first product line, our beliefs about the future integration of our technology into the production procedures of stem cell-based products and the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2017

2017

2016

2017

2016

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

1,495

5,227

3,679

2,405

1,848

General and administrative expenses

1,729

6,046

3,547

3,497

1,617

Other income

-

-

(280)

-

(280)

Operating loss

3,224

11,273

6,946

5,902

3,185

Financial expenses (income) due to warrants exercisable into shares

1,519

5,312

-

(1,461)

-

Other financial expenses (income), net

135

468

23

161

(5)

Total comprehensive loss

4,878

17,053

6,969

4,602

3,180

Loss per share:

Basic and diluted loss per share

0.045

0.158

0.088

0.042

0.039

Weighted average number of shares outstanding used to compute basic and diluted loss per share

108,034,218

108,034,218

79,113,097

108,462,728

81,456,571

Cellect Biotechnology Ltd

Consolidated Balance Sheet Data

ASSETS

See the original post:
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results - Markets Insider

Adipose cells (white/dyed red) next to an insulin-producing islet in the pancreas. Credit: IDM

Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis and liver cancer, but also the risk of type 2 diabetes and cardiovascular diseases. The cause for this is the altered secretion behavior of the fatty liver. It increasingly produces glucose, and unfavorable fats and proteins such as the hepatokine fetuin-A, all of which it releases into the bloodstream. Thus, the secreted substances of the fatty liver enter other organs and trigger further reactions. However, researchers did not know the effects of this "organ crosstalk," which organs are most affected, or what damage is caused by the hepatokine fetuin-A.

To elucidate the causal mechanisms and the resulting changes, researchers at the University of Tbingen studied the influence of fetuin-A on pancreatic adipose tissue. Approximately one-third of the pancreatic adipose tissue consists of adipose precursor cells (a type of stem cell) in addition to the mature adipose cells. If the pancreatic adipose cells are treated with fetuin-A in cell cultures, the mature adipose cells, in particular the adipose precursor cells in interaction with the islet cells, increasingly produce inflammation markers and immune-cell-attracting factors.

In addition, the researchers histologically analyzed tissue samples from 90 patients and found that the proportion of the pancreatic fat varied greatly. The number of defense cells of the immune system (monocytes/macrophages) was significantly increased in areas where many adipose cells had accumulated.

In a cohort of 200 subjects with an increased risk of type 2 diabetes, pancreatic fat content was measured by means of magnetic resonance imaging and compared with diabetes parameters. It was found that in persons who had already experienced a worsening of blood glucose regulation, an increased pancreatic fatty degeneration was associated with reduced insulin secretion. The investigations were carried out by Professor Hans Ulrich Hring and the Endocrinology Research Group, together with scientists from the Department of Experimental Radiology at the University of Tbingen.

These analyses, published in the journals Diabetologia and Diabetes/Metabolism Research and Reviews, suggest that a fatty liver, together with a fatty degeneration of the pancreas, triggers increased local immune cell infiltration and inflammation that accelerate the course of the disease.

However, adipose tissue is not harmful per se. It can even have protective effects. For example, adipose tissue located around blood vessels or the kidney has regenerative properties. "The factor that leads to pathological changes is fetuin-A, which is produced by the fatty liver," said Tbingen Professor Dorothea Siegel-Axel. As a result, instead of protecting tissue as before, the adipose tissue elicits inflammatory processes. This leads to a restriction of renal function. This is demonstrated by studies on arteries and the kidney, which have recently been published by the working group in the journal Scientific Reports.

"The statement that obesity in itself always has a disease-causing effect is too imprecise. Not until further parameters have been determined, such as fatty liver and hepatokine levels, as well as the elicited changes in other organs, can we obtain more exact indications as to whether a person has an increased disease risk or not," said Professor Hring, board member of the DZD and director of the IDM, summarizing the current results.

Explore further: Additional benefits of type 2 diabetes treatment found for non-alcoholic fatty liver disease patients

More information: Felicia Gerst et al, Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion, Diabetologia (2017). DOI: 10.1007/s00125-017-4385-1

Journal reference: Diabetologia Scientific Reports

Provided by: Deutsches Zentrum fuer Diabetesforschung DZD

Read more:
Fatty liver can cause damage to other organs via crosstalk - Medical Xpress

.......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........

Dr. Nichol: If your cockapoo has somewhat bowed rear legs, one or both of her knee caps (patellas) may slip out of its groove at the lower end of her thigh bone. Some patellas dislocate (luxate) just occasionally. A dog may skip for a few steps and then use the leg normally again after the patella slips back into the groove.

The knees of a dog with luxating patellas are vulnerable to injury. Your girls missed jump may have strained the supportive tendons that guide her patella. Rest and anti-inflammatory medication can help in the short term but the anatomy would still be structurally unsound. The only permanent solution will be surgical remodeling of the attachment of her patella and the groove in her lower femur.

Called a tibial crest rotation this surgery is a long-established procedure that many veterinarians are skilled at performing. But even with the geometric forces corrected, some chronic damage to a dogs tendons and cartilage will remain. Thats what makes stem cell therapy valuable.

While your girl is under anesthesia for knee surgery her doctor can make a small abdominal incision and remove a bit of fat. Your dogs very own stem cells (no risk of rejection) will be processed and shipped back overnight for injection into her knee. Over the following weeks the stem cells will stimulate regeneration of chronically inflamed tissues, resulting in a stronger and more comfortable joint.

Finally, stem cell therapy, also known as regenerative medicine, is not new. Veterinary orthopedists have used stem cells for 15 years to speed healing and reach better long-term outcomes.

Each week I make a short video or podcast to help bring out the best in pets. Sign up at no charge on my website, drjeffnichol.com. Every Tuesday it will arrive in your email. Ill also send you my free Pet Emergency and CPR guide.

Dr. Jeff Nichol treats behavior disorders at the Veterinary Emergency & Specialty Centers in Albuquerque and Santa Fe (505-792-5131). Questions on pet behavioral or physical concerns? For answers, Like my Facebook page at facebook.com/drjeffnichol or by mail to 4000 Montgomery NE, Albuquerque, NM 87109.

See the original post here:
Stem cells could benefit cockapoo's knee issue - Albuquerque Journal

PALM DESERT, Calif., Aug. 21, 2017 /PRNewswire/ --ASC Biosciences, Inc. (formerly Nevis Capital Corporation) ("ASC") (OTC Pink Open Markets: "ASCW") is pleased to announce it will appear on the award-winning program "Informed" hosted by Rob Lowe.

Informed is an award-winning program that highlights new stories and innovated concepts through ground breaking short-form and long-form documentary presentation. The program, which is anchored by a veteran production team with decades of industry experience, is able to effectively communicate the most critical stories to a wide and diverse audience. "Informed" is hosted by the inimitable Rob Lowe.

ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company that has a proprietary adult stem cell platform capable of forming nearly every tissue in the human body. These cells, Multipotent Adult Stem Cells ("MASCs"), will differentiate into cartilage, bone, tendon, muscle, ligament, fat, blood vessels, nerves, skin, etc. in humans. MASCs have apparent unlimited proliferation potential (do not reach replicative senescence) and have been shown to regenerate tissues by differentiating into the cell types at the site. MASCs lack the ability to cause a rejection response, and can thus be used as an allogenic transplant - which means that cells harvested from a single donor can be expanded in culture and the expanded cells can be used to treat hundreds, thousands, or millions of patients. TheMissionof ASC Biosciences is to provide surgeons around the world with our proprietary brand of unlimited allogeneic "Stem Cells in a Bottle" to be used in a wide variety of FDA Approved orthopedic and cosmetic therapies, resulting in permanent tissue regeneration; thus avoiding the repeat treatments commonly required in the current generation of approved stem cell therapies. ASC intends to establish an intellectual property portfolio that will provide proprietary dominion in the repair and regeneration of all human tissues. For more information visit:http://www.ascbio.comor @ASCbio1 on Facebook.

ASC trades on the OTC Pink Open Markets under the symbol: ASCW.

Forward-Looking StatementsCertain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about ASC Biosciences, Inc. industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.

Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Readers should review carefully reports or documents the Company files periodically with the OTC Markets -https://www.otcmarkets.com.

View original content:http://www.prnewswire.com/news-releases/asc-biosciences-inc-to-appear-on-the-informed-series-hosted-by-rob-lowe-300507183.html

SOURCE ASC Biosciences, Inc.

Read this article:
ASC Biosciences, Inc. to appear on the "Informed" series hosted by Rob Lowe - Markets Insider

If you can still read this, congratulations youre not blind from staring directly into the eclipse (yet).

Then again, eye damage from viewing a solar eclipse can take days to manifest. Using whatever eyesight they had left, freaked out Americans turned to Google for advice.

Google Trends showed a sharp uptick in searches for SEO-friendly phrases like solar eclipse headache, solar eclipse blind, eyes hurt, seeing spots, solar retinopathy, headache after eclipse, accidentally looked at eclipse, headache after solar eclipse, burned retinas, eclipse headache, and eclipse blind.

Experts warn that staring into a solar eclipse for any amount of time even just a few seconds could result in permanent blurry vision or blindness because the dark moon passing over the sun essentially cancels out the normal burning sensation that makes people look away from bright light.

Its often hard to tell whether damage has occurred, since the exposure is painless and symptoms can crop up for weeks afterward. Symptoms that suggest short-term damage include eye pain and light sensitivity, often occurring within 24 hours of exposure, Linda Chous, an ophthalmologist and chief eye care officer for UnitedHealthcare, told NBC. Long-term symptoms include a loss of central vision including a dark spot or hole in vision typically presenting anytime up to two weeks after exposure.

But sadly for President Donald Trump, who was photographed looking directly into the eclipse twice in a span of less than five minutes, Americans seem less concerned with his ocular health.

Searches for Trump blind actually peaked in November 2016 around the same time he promised to put his businesses into a blind trust in an effort to prevent a conflict of interest between the White House and the Trump Organization.

In that sense, Trump does not appear to be blind at all according to Propublica, the trusts terms have since been changed to allow Trump to withdraw money from the businesses whenever he wants.

See original here:
America is genuinely worried it went blind today - VICE News

The website PreventBlindness.org, an organization committed to education around blindness and "bringing Americans to eye care," has published a handy guide to safely viewing a solar eclipse and what it can potentially do to your eyes if they aren't shielded by the proper protection. As PreventBlindness.org explains, looking at a solar eclipse too long can cause "solar retinopathy," or retinal burns that destroy the cells that help you see. Unfortunately, the damage occurs with no pain, due to the fact that there are no nerve endings in that part of your eyes, and it can take "a few hours to a few days after viewing the solar eclipse to realize the damage that has occurred."

All of which sounds absolutely terrifying, an information cocktail that seems like a surefire rocket fuel to the planet Hypochondria. Still, you can never be too careful, especially if you're already experiencing discomfort in the eyes. These are the specific symptoms PreventBlindness.org stipulates that you should look out for:

See the article here:
Here Are the Eye Damage Symptoms to Worry About After Watching the Eclipse - Thrillist

Perhaps some of the region's climate-change deniers even readand believedan article appearing in The Forum ('Fargo-Moorhead will be in path of total solar eclipse in 2099'). To be specific, this eclipse will begin at 10:37 a.m. on Monday, Sept. 14, 2099.

That calculation is the result of engineering and astronomy, or in a word: science.

So, why might some climate-change deniers, such as Inhofe, blindly confess that God controls our climate, but then have no problem believing that mani.e., the scientific methodis capable of predicting celestial events decades away down to the very minute?

Follow the money. Citing Oil Change International, the website DeSmogBlog asserts that Inhofe has received more than $2 million in political contributions from the coal and oil industry. One of his top benefactors is Koch Industries ($77,550 since 1999). ExxonMobil has contributed more than $35,000 since 1999.

But Oklahoma is a long way from North Dakota. Surely, that type of financial support doesn't cloud our politicians' vision, right?

Well ... according to OpenSecrets.org, Sen. John Hoeven received $492,228 from the energy/natural resources sector (oil and gas, electric utilities and mining industries) during the 2015-2016 cyclean amount placing him among the top-20 recipients in Congress. At the same time, Sen. Heidi Heitkamp received $155,155 and Rep. Kevin Cramer received $337,200.

Oh, by the way, OpenSecrets.org says Inhofe received only $64,000 from the energy/natural resources sector during the same period.

Hulse lives in Fargo.

More:
Letter: Political blindness and the total eclipse - INFORUM